FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 67712

Company▼ Bearish

Phase 3 results posted: A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) — Janssen Research & Development, LLC

KINDCompany
DIRECTION▼ Bearish
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN2026-10-06 12:00 UTC
LAST UPDATE2026-10-06 12:00 UTC
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

A terminated Phase 3 depression trial removes a potential pipeline asset and signals efficacy or safety problems.

Terminated depression trial weakens pipeline outlook
CATALYST TO WATCH

Disclosure of termination reasons

MAIN RISK

Further pipeline attrition in CNS

FULL DISPATCH

Sponsor: Janssen Research & Development, LLC; Status: Terminated; Conditions: Depressive Disorder, Major; Interventions: Aticaprant; Enrollment: 871 (actual); First posted: 2022-08-26; Results posted: 2026-10-06; NCT: NCT05518149

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED
№ 01clinicaltrialsclinicaltrials.gov · PRIMARY2026-10-06 12:00 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.